Drugs / AD-214-02
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04622358 | Dec 2020 → Mar 2021 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-214-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04622358 ↗ |